SOPHiA GENETICS Expands Perceptive Credit Facility With New $25 Million Term Loan Capacity and Additional Warrants

SOPHiA GENETICS ( (SOPH) ) just unveiled an update.

On January 23, 2026, SOPHiA GENETICS SA amended its existing credit agreement with Perceptive Credit Holdings IV, LP, securing an additional $25 million in term loan commitments split into two $12.5 million tranches: a Tranche C loan that can be drawn under customary conditions and a Tranche D loan that becomes available once trailing 12‑month revenue exceeds $85 million, with both tranches carrying Term SOFR plus 6.25% interest and maturing in 2029. In connection with the amendment, the company also amended and restated a warrant certificate to grant Perceptive the immediate right to purchase 75,000 additional ordinary shares, plus further rights to acquire 100,000 shares upon any draw of the Tranche C loan and another 100,000 shares upon any draw of the Tranche D loan, reinforcing the existing lien structure under its Swiss security documents; the move provides SOPHiA GENETICS with contingent growth capital while introducing potential future equity dilution for shareholders as the warrants become exercisable over a 10‑year period.

The most recent analyst rating on (SOPH) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on SOPHiA GENETICS stock, see the SOPH Stock Forecast page.

Spark’s Take on SOPH Stock

According to Spark, TipRanks’ AI Analyst, SOPH is a Neutral.

SOPHiA GENETICS’ overall stock score is primarily influenced by its financial performance challenges, including profitability and cash flow issues. While technical analysis shows positive momentum, valuation concerns due to ongoing losses weigh heavily. The earnings call highlights strong growth and strategic initiatives, but these are not enough to offset the financial challenges.

To see Spark’s full report on SOPH stock, click here.

More about SOPHiA GENETICS

SOPHiA GENETICS SA is a Swiss, publicly listed health‑tech company that provides data-driven analytics and cloud-based software solutions, primarily focused on genomics and clinical diagnostics for healthcare and life sciences customers. Operating globally from its headquarters in Rolle, Switzerland, the company targets hospitals, laboratories and research institutions seeking advanced data analytics to support precision medicine and clinical decision-making.

Average Trading Volume: 162,808

Technical Sentiment Signal: Buy

Current Market Cap: $360.9M

For detailed information about SOPH stock, go to TipRanks’ Stock Analysis page.